TScan Therapeutics, Inc. Profile Avatar - Palmy Investing

TScan Therapeutics, Inc.

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic m…

Biotechnology
US, Waltham [HQ]
Supply · Problems · Premarket · Compliance

Supply Analysis

End of TCRX's Analysis
CIK: 1783328 CUSIP: 89854M101 ISIN: US89854M1018 LEI: - UEI: -
Secondary Listings
TCRX has no secondary listings inside our databases.